

<b>Reference:</b>	FOI.12093.23
<b>Subject:</b>	Multiple Myeloma
<b>Date of Request:</b>	30 June 2023

**Requested:**

- Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
- Of the multiple myeloma patients over the past 6 month, how many were treated with the following:
  - Belantamab Mafodotin [Blenrep]
  - Bortezomib [Velcade] monotherapy or with dexamethasone
  - Bortezomib, thalidomide and dexamethasone [VTD]
  - Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
  - Carfilzomib [Kyprolis] and dexamethasone
  - Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone
  - Daratumumab [Darzalex] monotherapy
  - Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
  - Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
  - Elranatamab
  - Idecabtagene vicleucel [Abecma]
  - Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
  - Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)
  - Lenalidomide [Revlimid] monotherapy
  - Lenalidomide [Revlimid] and dexamethasone
  - Pomalidomide [Imnovid] and dexamethasone
  - Selinexor and dexamethasone
  - Talquetamab
  - Teclistamab [Tecvayli]
  - Any other systemic anti-cancer therapy

**Response:**

- Hywel Dda University Health Board (UHB) is currently treating approximately 150 patients for Multiple Myeloma. Due to the timeframe given and the ever-changing picture, the figure provided is an approximation.
- The number of patients treated for Multiple Myeloma with the named treatments between 1 January and 30 June 2023 is provided within the table below.

<b>Treatment</b>	<b>Number</b>
Belantamab Mafodotin [Blenrep]	*
Bortezomib [Velcade] monotherapy or with dexamethasone	*
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	*
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	15
Carfilzomib [Kyprolis] and Dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]	*
Daratumumab [Darzalex] monotherapy	23
Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVD or DBd)	*
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	16
Elranatamab	0
Idecabtagene vicleucel [Abecma]	0
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	*
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]	*
Lenalidomide [Revlimid] monotherapy	14
Lenalidomide [Revlimid] and Dexamethasone	26
Pomalidomide [Imnovid] and Dexamethasone	*
Selinexor and dexamethasone	0
Talquetamab	0
Teclistamab [Tecvayli]	0
Any other systemic anti-cancer treatment	11

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.